Structure via PubChem · Public domain (PubChem)
fesoterodine
Sign in to saveAlso known as SPM-8272, SPM-907, Toviaz®
Fesoterodine (INN, used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB). It was approved by the European Medicines Agency in April 2007, the US Food and Drug Administration on October 31, 2008 and Health Canada on February 9, 2012.
Chemical data
- Formula
- C26H37NO3
- Molecular weight
- 411.6 g/mol
- IUPAC name
- [2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate
- SMILES
- CC(C)C(=O)OC1=C(C=C(C=C1)CO)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2
- InChIKey
- DCCSDBARQIPTGU-HSZRJFAPSA-N
- XLogP
- 5.5
- Polar surface area
- 49.8 Ų
- H-bond donors
- 1
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2007
- Admin. routes
- oral
- Indications
- Urinary incontinence, Neurogenic bladder, overactive bladder, autonomic dysreflexia
via ChEMBL · EBI
Research
354 papers- Fesoterodine.2012
- Fesoterodine.2006
- Fesoterodine.Drugs · 2009
- Fesoterodine: Pharmacological properties and clinical implications.European journal of pharmacology · 2018
- Review of fesoterodine.Expert opinion on drug safety · 2011
via PubMed
Wikidata facts
- Has part
- carbon
- Mass
- 411.2773
- Has use
- medication
Show 5 more facts
- Commons category
- Fesoterodine
- chemical formula
- C₂₆H₃₇NO₃
- isomeric SMILES
- CC(C)C(=O)OC1=C(C=C(C=C1)CO)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2
- canonical SMILES
- CC(C)C(=O)OC1=C(C=C(C=C1)CO)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2
- defined daily dose
- 4
Sources (3)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- Efficacy
- References
Fesoterodine (INN, used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB). It was approved by the European Medicines Agency in April 2007, the US Food and Drug Administration on October 31, 2008 and Health Canada on February 9, 2012.
Fesoterodine is a prodrug. It is broken down into its active metabolite, desfesoterodine, by plasma esterases.
Excerpted from Wikipedia’s “fesoterodine” article, available under the CC BY-SA 4.0 licence.